Contract 75A50120C00171
Invirsa, Inc. · Department Of Health And Human Services · September 25, 2020
Invirsa, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 25, 2020 for $16.41 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Columbus, OH. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses cost sharing contract pricing. The most recent modification was on July 17, 2024. If all options are exercised, the contract could reach $32.67 million.
Contract details
- PIID
- 75A50120C00171
- Award type
- Definitive Contract
- Pricing
- Cost Sharing
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- R&D- Other Research And Development (Advanced Development)
- Place of performance
- Columbus, OH
- First action
- September 25, 2020
- Latest action
- July 17, 2024
Description
EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3.
Modification timeline
-
July 17, 2024Mod P00010 · Funding Only Action$20.03M
-
September 25, 2020Base awardINV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3.$14.44M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50120C00171?
Contract 75A50120C00171 is a federal contract awarded to Invirsa, Inc. by Department Of Health And Human Services on September 25, 2020 for $16.41 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 1 time since the base award.
Who won contract 75A50120C00171?
Invirsa, Inc. won contract 75A50120C00171 from Department Of Health And Human Services.
How much is contract 75A50120C00171 worth?
Contract 75A50120C00171 has obligated $16.41 million to date, with a total potential value of $32.67 million if all options are exercised.